Morningstar maintains fair value for CSL despite underperformance
BUZZ-Morningstar maintains fair value for CSL despite underperformance ** Morningstar keeps A$165 fair value estimate despite headwinds faced by Australia's CSL Ltd CSL.AX
** Earlier this year, the biotechnology giant cut its annual profit citing regulatory headwinds and weak performance including other reasons
** The Investment research firm says shares are undervalued, says it is more optimistic on co's stock than the market on plasma demand and margins
** Morningstar sees co's immunoglobulin revenue to grow at a 10-year compound annual growth rate (CAGR) of 5% on higher volumes from population growth, rising diagnosis rates including others
** Also forecasts plasma gross margins to lift to 100 basis points till FY35, cites efficiency initiatives and rationalization of high-cost collection centers
** Says market for plasma products has become increasingly competitive and most cost savings will be offset by price competition
** Adds, separation of CSL Seqirus to help CSL to refocus on the core business
** YTD, CSL down 46.4%, as of firm's last close
(Reporting by Aamir Sheik Khalid in Bengaluru)
Recent news on Morningstar
See all newsAustralia's Magellan Financial hits 1-1/2-year low; Morningstar cuts fair value estimate on weaker outlook
Street View: Philip Morris to weather cost hit as smoke-free revenue growth in focus
Pressure on lower-income US households raises delinquency risks, Morningstar DBRS says
UK gilt investors expect budget to pass without market drama, Morningstar says
UK gilt investors expect budget to pass without market drama, Morningstar says